Patent intelligence · US
US 12018015
Methods and compositions for targeting PD-L1
Methods and compositions for targeting PD-L1
Patent details — US 12018015
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2024
- Expiration
- Jun 20, 2044
- Applicant
- Aligos Therapeutics, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/658
Quick answer
US 12018015 (Methods and compositions for targeting PD-L1) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aligos Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/658, A61K45/06, A61P
More from Aligos Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384779
Bicyclic compounds
granted -
US 12252481
Anti-viral compounds
granted -
US 12180192
Modulators of THR-β and methods of use thereof
granted -
US 12129469
Modified short interfering nucleic acid (siNA) molecules and uses thereof
granted -
US 12065428
Anti-viral compounds
granted -
US 11957683
Bicyclic compounds
granted -
US 11952374
Bicyclic compounds
granted
Related coverage
Frequently asked questions
What is US patent 12018015?
US 12018015 (Methods and compositions for targeting PD-L1) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12018015?
Aligos Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 12018015 expire?
Our index shows an expiration date of Jun 20, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.